

Electronic Acknowledgement Receipt

EFS ID:	1434992
Application Number:	10603006
International Application Number:	
Confirmation Number:	1649
Title of Invention:	Cancerous disease modifying antibodies
First Named Inventor/Applicant Name:	David S. F. Young
Correspondence Address:	Michael A. Slavin McHale & Slavin, P.A. 2855 PGA Boulevard - Palm Beach Gardens FL 33410 US 561 625 6572 -
Filer:	Ferris Harvey Lander
Filer Authorized By:	
Attorney Docket Number:	2056.023
Receipt Date:	12-JAN-2007
Filing Date:	23-JUN-2003
Time Stamp:	11:53:12
Application Type:	Utility

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 1945
RAM confirmation Number	1365

Deposit Account	501820
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	2056023ExtensionoftimeOA71206.pdf	62354	no	1

Warnings:

Information:

2		2056023PetitionOA71206.pdf	98795	yes	6
---	--	----------------------------	-------	-----	---

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Petition for review by the Office of Petitions.		1	2	
	Amendment - After Non-Final Rejection		3	3	
	Specification		4	4	
	Applicant Arguments/Remarks Made in an Amendment		5	6	

Warnings:

Information:

3		2056023ResponseOA71206.pdf	1007840	yes	37
---	--	----------------------------	---------	-----	----

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	2	
	Specification		3	8	
	Claims		9	17	
	Drawings		18	18	
	Applicant Arguments/Remarks Made in an Amendment		19	29	
	Drawings		30	31	

	Applicant Arguments/Remarks Made in an Amendment		32	37
Warnings:				
Information:				
4	Terminal Disclaimer Filed	2056023Terminaldisclaimer1.pdf	72931	no 1
Warnings:				
Information:				
5	Terminal Disclaimer Filed	2056023Terminaldisclaimer2.pdf	80252	no 1
Warnings:				
Information:				
6	Terminal Disclaimer Filed	2056023Terminaldisclaimer3.pdf	80356	no 1
Warnings:				
Information:				
7	Terminal Disclaimer Filed	2056023Terminaldisclaimer4.pdf	80244	no 1
Warnings:				
Information:				
8	Terminal Disclaimer Filed	2056023Terminaldisclaimer5.pdf	80087	no 1
Warnings:				
Information:				
9	Terminal Disclaimer Filed	2056023Terminaldisclaimer6.pdf	80689	no 1
Warnings:				
Information:				
10	Terminal Disclaimer Filed	2056023Terminaldisclaimer7.pdf	80534	no 1
Warnings:				
Information:				
11	Fee Worksheet (PTO-06)	fee-info.pdf	8433	no 2
Warnings:				
Information:				
Total Files Size (in bytes):			1732515	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.